Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & DohmefiledCriticalMerck Sharp & Dohme
Publication of PE128999A1publicationCriticalpatent/PE128999A1/es
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Agricultural Chemicals And Associated Chemicals
(AREA)
Cosmetics
(AREA)
Nitrogen Condensed Heterocyclic Rings
(AREA)
Abstract
SE REFIERE A 3-(5-METILISOXAZOL-3-IL)-5-(1-METIL-1,2,3-TRIAZOL-4-IL)METOXI-1,2,4-TRIAZOLO[3,4-a]FTALAZINA QUE SE UNE AL RECEPTOR GABA a QUE CONTIENE LA SUBUNIDAD 5O Y PUEDE SER UTIL PARA TRATAR TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL COMO DELIRIO, DEMENCIA, TRASTORNOS AMNESICOS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE HACER REACCIONAR UN REACTIVO METILANTE TAL COMO HEXAMETILDISILAZIDA DE LITIO CON 3-(5-METILISOXAZOL-3-IL)-6-(1H-1,2,3-TRIAZOL-5-IL)METILOXI-1,2,4-TRIAZOLO[3,4-a]FTALAZINA
Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine